Spotlight on Internal Medicine

Credits: 0.25 AAPA / CME / CPE
Optimizing Diagnosis and Management of Nontuberculous Mycobacterial Lung Disease—NTM Lung Disease Curbside Consults: Improving Patient Adherence - Managing Adverse Events
David E. Griffith, MD, FACP, FCCP, ATSF
Vindico

Optimizing Diagnosis and Management of Nontuberculous Mycobacterial Lung Disease—NTM Lung Disease Curbside Consults: Improving Patient Adherence - Managing Adverse Events

Start

Activity Details

Free CME/CPE/AAPA
0.25 AMA PRA Category 1 Credit(s)
0.25 ACPE Contact Hour(s)
0.25 AAPA Category 1 CME Credit(s)
Released: March 31, 2021
Expires: March 30, 2022
15 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists, pulmonologists, pharmacists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with nontuberculous mycobacterial lung disease.

Learning Objective

Upon successful completion of the activity, participants should be better able to examine the strategies to manage adverse effects associated with treatment of NTM-LD, including approaches to improve treatment adherence.

Activity Description

In this Curbside Consult, Drs. Charles Daley and David Griffith discuss strategies for improving treatment adherence and managing medication-related adverse events in a 77-year-old patient with Mycobacterium avium complex lung disease.

Statement of Educational Need

Nontuberculous mycobacteria (NTM) infection is becoming more widespread in the United States and worldwide. Pulmonary disease is the most common manifestation of NTM infection, often occurring in patients with underlying lung diseases such as cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. A disproportionate number of patients with NTM lung disease are older adults or immunocompromised individuals, with the potential for chronic infection requiring long-term treatment. Therapies with improved efficacy and safety are critical for optimal management of this increasingly prevalent disease. Additionally, education is required to better enable clinicians to make a timely, accurate diagnosis and deliver care informed by the latest clinical evidence and guidelines.

Activity Chair

David E. Griffith, MD, FACP, FCCP, ATSF
Professor of Medicine
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: Insmed
Speakers Bureau: Insmed
Non-CME Service Fees: Insmed
Contracted Research: Insmed

Faculty

Charles L. Daley, MD
Professor of Medicine
National Jewish Health and University of Colorado
Chief, Division of Mycobacterial and Respiratory Infections
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: AN2, Cipla, Insmed, Matinas, Paratek, Spero
Contracted Research: Insmed

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Jennifer Frederick, PharmD, BCPS
Disclosure: No relevant financial relationships to disclose.

Linda A. Giarraputo, PA-C
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Accreditation Council for Pharmacy EducationVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is acceptable for 0.25 contact hour(s) of Accreditation Council for Pharmacy Education (ACPE) Continuing Education Credit. The ACPE Universal Program Number is 0482-0000-21-005-H01-P, effective 03/31/2021. This is a knowledge-based activity and there is no fee to attend.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor.

This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 0.25AAPA Category 1 CME Credit(s). Approval is valid from 3/31/2021 to 3/30/2022. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-202344.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate, AAPA Category 1 CME Certificate, or ACPE Statement of Credit.

Statement of Commercial Support

This activity is supported by an educational grant from Insmed.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/CPE/AAPA
0.25 AMA PRA Category 1 Credit(s)
0.25 ACPE Contact Hour(s)
0.25 AAPA Category 1 CME Credit(s)
Released: March 31, 2021
Expires: March 30, 2022
15 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists, pulmonologists, pharmacists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with nontuberculous mycobacterial lung disease.

Learning Objective

Upon successful completion of the activity, participants should be better able to examine the strategies to manage adverse effects associated with treatment of NTM-LD, including approaches to improve treatment adherence.

Activity Description

In this Curbside Consult, Drs. Charles Daley and David Griffith discuss strategies for improving treatment adherence and managing medication-related adverse events in a 77-year-old patient with Mycobacterium avium complex lung disease.

Statement of Educational Need

Nontuberculous mycobacteria (NTM) infection is becoming more widespread in the United States and worldwide. Pulmonary disease is the most common manifestation of NTM infection, often occurring in patients with underlying lung diseases such as cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. A disproportionate number of patients with NTM lung disease are older adults or immunocompromised individuals, with the potential for chronic infection requiring long-term treatment. Therapies with improved efficacy and safety are critical for optimal management of this increasingly prevalent disease. Additionally, education is required to better enable clinicians to make a timely, accurate diagnosis and deliver care informed by the latest clinical evidence and guidelines.

Activity Chair

David E. Griffith, MD, FACP, FCCP, ATSF
Professor of Medicine
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: Insmed
Speakers Bureau: Insmed
Non-CME Service Fees: Insmed
Contracted Research: Insmed

Faculty

Charles L. Daley, MD
Professor of Medicine
National Jewish Health and University of Colorado
Chief, Division of Mycobacterial and Respiratory Infections
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: AN2, Cipla, Insmed, Matinas, Paratek, Spero
Contracted Research: Insmed

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Jennifer Frederick, PharmD, BCPS
Disclosure: No relevant financial relationships to disclose.

Linda A. Giarraputo, PA-C
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Accreditation Council for Pharmacy EducationVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is acceptable for 0.25 contact hour(s) of Accreditation Council for Pharmacy Education (ACPE) Continuing Education Credit. The ACPE Universal Program Number is 0482-0000-21-005-H01-P, effective 03/31/2021. This is a knowledge-based activity and there is no fee to attend.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor.

This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 0.25AAPA Category 1 CME Credit(s). Approval is valid from 3/31/2021 to 3/30/2022. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-202344.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate, AAPA Category 1 CME Certificate, or ACPE Statement of Credit.

Statement of Commercial Support

This activity is supported by an educational grant from Insmed.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Internal Medicine Presentations

1.25 CME / MOC
Vindico
Reducing Influenza Complications in High-Risk Patients: A Virtual Symposium With Challenging Clinical Cases

Reducing Influenza Complications in High-Risk Patients: A Virtual Symposium With Challenging Clinical Cases

Start

Activity Details

Free CME/MOC
1.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
1.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Director, Infection Control Section
Department of Infectious Diseases/Infection Control, and Employee Health
University of Texas MD Anderson Cancer Center
Houston, TX
  • Disclosure:
  • Consulting Fee: ADMA Biologics, Ansun BioPharma, Chimerix, Genentech, Janssen, Kyorin, Partner Therapeutics, Pulmotect, ReViral, Symbio
  • Speakers Bureau: Merck, Oxford Immunotec, Xenex
  • Contracted Research: Ansun, Chimerix, Gilead, Karius, Merck, Novartis, Oxford Immunotec, Shire/Takeda, Xenex, Viracor
  • Ownership Interest: Xenex


John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
  • Disclosure:
  • Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
  • Speakers Bureau: Sanofi Pasteur


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Introduction
Paul G. Auwaerter, MD, MBA, FIDSA

Influenza Management: What’s New in 2020?
Paul G. Auwaerter, MD, MBA, FIDSA

Challenging Case 1: Diagnosing and Treating Flu in the Nursing Home Patient With COPD
John J. Russell, MD

Challenging Case 2: The Pediatric Asthmatic Patient With Symptoms of Flu
John J. Russell, MD

Challenging Case 3: Managing Flu in an Immunocompromised Patient
Roy F. Chemaly, MD, MPH, FIDSA, FACP

Key Takeaways and Conclusion
Paul G. Auwaerter, MD, MBA, FIDSA

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
1.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
1.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Director, Infection Control Section
Department of Infectious Diseases/Infection Control, and Employee Health
University of Texas MD Anderson Cancer Center
Houston, TX
  • Disclosure:
  • Consulting Fee: ADMA Biologics, Ansun BioPharma, Chimerix, Genentech, Janssen, Kyorin, Partner Therapeutics, Pulmotect, ReViral, Symbio
  • Speakers Bureau: Merck, Oxford Immunotec, Xenex
  • Contracted Research: Ansun, Chimerix, Gilead, Karius, Merck, Novartis, Oxford Immunotec, Shire/Takeda, Xenex, Viracor
  • Ownership Interest: Xenex


John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
  • Disclosure:
  • Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
  • Speakers Bureau: Sanofi Pasteur


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Introduction
Paul G. Auwaerter, MD, MBA, FIDSA

Influenza Management: What’s New in 2020?
Paul G. Auwaerter, MD, MBA, FIDSA

Challenging Case 1: Diagnosing and Treating Flu in the Nursing Home Patient With COPD
John J. Russell, MD

Challenging Case 2: The Pediatric Asthmatic Patient With Symptoms of Flu
John J. Russell, MD

Challenging Case 3: Managing Flu in an Immunocompromised Patient
Roy F. Chemaly, MD, MPH, FIDSA, FACP

Key Takeaways and Conclusion
Paul G. Auwaerter, MD, MBA, FIDSA

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME / MOC
Vindico
Influenza: Reducing Complications in High-Risk Patients Through Advanced Treatment Options – Curbside Consult: Treating Flu in a 69-year-old Patient With COPD

Influenza: Reducing Complications in High-Risk Patients Through Advanced Treatment Options – Curbside Consult: Treating Flu in a 69-year-old Patient With COPD

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
0.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
  • Disclosure:
  • Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
  • Speakers Bureau: Sanofi Pasteur


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Curbside Consult: Treating Flu in a 69-year-old Patient With COPD
Paul G. Auwaerter, MD, MBA, FIDSA and John J. Russell, MD

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
0.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
  • Disclosure:
  • Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
  • Speakers Bureau: Sanofi Pasteur


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Curbside Consult: Treating Flu in a 69-year-old Patient With COPD
Paul G. Auwaerter, MD, MBA, FIDSA and John J. Russell, MD

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME / MOC
Vindico
Influenza: Reducing Complications in High-Risk Patients Through Advanced Treatment Options – Curbside Consult: Managing Flu in an Immunocompromised Patient

Influenza: Reducing Complications in High-Risk Patients Through Advanced Treatment Options – Curbside Consult: Managing Flu in an Immunocompromised Patient

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
0.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Director, Infection Control Section
Department of Infectious Diseases/Infection Control, and Employee Health
University of Texas MD Anderson Cancer Center
Houston, TX
  • Disclosure:
  • Consulting Fee: ADMA Biologics, Ansun BioPharma, Chimerix, Genentech, Janssen, Kyorin, Partner Therapeutics, Pulmotect, ReViral, Symbio
  • Speakers Bureau: Merck, Oxford Immunotec, Xenex
  • Contracted Research: Ansun, Chimerix, Gilead, Karius, Merck, Novartis, Oxford Immunotec, Shire/Takeda, Xenex, Viracor
  • Ownership Interest: Xenex


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Curbside Consult: Managing Flu in an Immunocompromised Patient
Paul G. Auwaerter, MD, MBA, FIDSA and Roy F. Chemaly, MD, MPH, FIDSA, FACP

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
0.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Director, Infection Control Section
Department of Infectious Diseases/Infection Control, and Employee Health
University of Texas MD Anderson Cancer Center
Houston, TX
  • Disclosure:
  • Consulting Fee: ADMA Biologics, Ansun BioPharma, Chimerix, Genentech, Janssen, Kyorin, Partner Therapeutics, Pulmotect, ReViral, Symbio
  • Speakers Bureau: Merck, Oxford Immunotec, Xenex
  • Contracted Research: Ansun, Chimerix, Gilead, Karius, Merck, Novartis, Oxford Immunotec, Shire/Takeda, Xenex, Viracor
  • Ownership Interest: Xenex


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Curbside Consult: Managing Flu in an Immunocompromised Patient
Paul G. Auwaerter, MD, MBA, FIDSA and Roy F. Chemaly, MD, MPH, FIDSA, FACP

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME / MOC
Vindico
Influenza: Reducing Complications in High-Risk Patients Through Advanced Treatment Options – Curbside Consult: An Adult Patient With Asthma and Symptoms of Flu

Influenza: Reducing Complications in High-Risk Patients Through Advanced Treatment Options – Curbside Consult: An Adult Patient With Asthma and Symptoms of Flu

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
0.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
  • Disclosure:
  • Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
  • Speakers Bureau: Sanofi Pasteur


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Curbside Consult: An Adult Patient With Asthma and Symptoms of Flu
Paul G. Auwaerter, MD, MBA, FIDSA and John J. Russell, MD

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
0.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
  • Disclosure:
  • Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
  • Speakers Bureau: Sanofi Pasteur


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Curbside Consult: An Adult Patient With Asthma and Symptoms of Flu
Paul G. Auwaerter, MD, MBA, FIDSA and John J. Russell, MD

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.00 CME / CNE / CPE
Integrity Continuing Education, Inc.
Clearing the Air: Recognizing the Role of Eosinophils and IL-5 Inhibitors in Severe Asthma and Associated Conditions

Clearing the Air: Recognizing the Role of Eosinophils and IL-5 Inhibitors in Severe Asthma and Associated Conditions

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: June 25, 2020
Expires: June 25, 2021
1 hour to complete

Accredited By

This CME activity for ACCME credit is provided by Integrity Continuing Education.
This CE activity for ANCC and ACPE credit is jointly provided by Global Education Group and Integrity Continuing Education.

Target Audience

This educational initiative has been designed for pulmonologists, allergists, fellows, medical residents, nurse practitioners, physician assistants, nurses, and other allied health care professionals who manage patients with asthma and other eosinophilic-associated diseases.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe the role of eosinophilia in severe asthma and EGPA
  • Explain why severe asthma comorbidities and rare orphan diseases have an impact on treatment of severe asthma
  • Differentiate between available biologic therapies and evaluate their impact on lung function, asthma exacerbations, and dependence on oral corticosteroids

Activity Description

This program was designed to increase the clinician’s understanding of severe eosinophilic diseases that target the lungs and enable them to differentiate between available treatments to facilitate improved symptoms, lighter disease burden, fewer exacerbations, and reduced oral corticosteroids reliance.

Statement of Educational Need

In the area of severe asthma, an emerging understanding of disease pathophysiology has identified therapeutic targets leading to better tolerated and more selective treatments. Biologics now fill a previously unmet need for effective treatment options for patients with eosinophilic-mediated respiratory disease. However, there are a number of eosinophil-mediated lung diseases associated with severe asthma that remain poorly understood, including eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES). Understanding the drivers of diseases associated with and sometimes concomitant to severe asthma is critical to effective management, as is the ability to identify which patients might benefit from available therapeutic agents.

Faculty

J. Mark FitzGerald, MB, MD, FRCPC (Faculty Presenter)
Professor of Respiratory Medicine
University of British Columbia
Vancouver, British Columbia

Disclosure:
Consulting Fees: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi Regeneron, Teva Pharmaceutical Industries Ltd.

Fees for Non-CME/CE: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi Regeneron, Teva Pharmaceutical Industries Ltd.

Contracted Research/Funds paid directly to UBC: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Gossamer Bio, Novartis Pharmaceuticals Corporation, Sanofi Regeneron


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education (Integrity CE) and Global Education Group (Global) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity CE and Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following project managers/planners: Lindsay Borvansky, Ashley Cann, Donna Fausak, Andrea Funk, Amy Khalil, Liddy Knight, Ashley Marostica, RN, MSN, Patima Tanapat, PhD, reported that they or their spouses/life partners, have no financial relationships or relationships to products or devices with commercial interests related to the content of this CE activity.

Designation of Credit

Physician Credit
Integrity Continuing Education is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Integrity Continuing Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.0 contact hour(s) is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number 0530-9999-20-069-H01-P)

This is a knowledge-based activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME/CE credit for this activity. During the period of June 25, 2020 through June 25, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. For pharmacist/ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.

Statement of Commercial Support

This activity is supported by an educational grant from GlaxoSmithKline LLC.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education and GlaxoSmithKline do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education or GlaxoSmithKline. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions about the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or information@integrityce.com.

For information about the ANCC or ACPE accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: June 25, 2020
Expires: June 25, 2021
1 hour to complete

Accredited By

This CME activity for ACCME credit is provided by Integrity Continuing Education.
This CE activity for ANCC and ACPE credit is jointly provided by Global Education Group and Integrity Continuing Education.

Target Audience

This educational initiative has been designed for pulmonologists, allergists, fellows, medical residents, nurse practitioners, physician assistants, nurses, and other allied health care professionals who manage patients with asthma and other eosinophilic-associated diseases.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe the role of eosinophilia in severe asthma and EGPA
  • Explain why severe asthma comorbidities and rare orphan diseases have an impact on treatment of severe asthma
  • Differentiate between available biologic therapies and evaluate their impact on lung function, asthma exacerbations, and dependence on oral corticosteroids

Activity Description

This program was designed to increase the clinician’s understanding of severe eosinophilic diseases that target the lungs and enable them to differentiate between available treatments to facilitate improved symptoms, lighter disease burden, fewer exacerbations, and reduced oral corticosteroids reliance.

Statement of Educational Need

In the area of severe asthma, an emerging understanding of disease pathophysiology has identified therapeutic targets leading to better tolerated and more selective treatments. Biologics now fill a previously unmet need for effective treatment options for patients with eosinophilic-mediated respiratory disease. However, there are a number of eosinophil-mediated lung diseases associated with severe asthma that remain poorly understood, including eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES). Understanding the drivers of diseases associated with and sometimes concomitant to severe asthma is critical to effective management, as is the ability to identify which patients might benefit from available therapeutic agents.

Faculty

J. Mark FitzGerald, MB, MD, FRCPC (Faculty Presenter)
Professor of Respiratory Medicine
University of British Columbia
Vancouver, British Columbia

Disclosure:
Consulting Fees: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi Regeneron, Teva Pharmaceutical Industries Ltd.

Fees for Non-CME/CE: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi Regeneron, Teva Pharmaceutical Industries Ltd.

Contracted Research/Funds paid directly to UBC: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Gossamer Bio, Novartis Pharmaceuticals Corporation, Sanofi Regeneron


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education (Integrity CE) and Global Education Group (Global) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity CE and Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following project managers/planners: Lindsay Borvansky, Ashley Cann, Donna Fausak, Andrea Funk, Amy Khalil, Liddy Knight, Ashley Marostica, RN, MSN, Patima Tanapat, PhD, reported that they or their spouses/life partners, have no financial relationships or relationships to products or devices with commercial interests related to the content of this CE activity.

Designation of Credit

Physician Credit
Integrity Continuing Education is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Integrity Continuing Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.0 contact hour(s) is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number 0530-9999-20-069-H01-P)

This is a knowledge-based activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME/CE credit for this activity. During the period of June 25, 2020 through June 25, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. For pharmacist/ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.

Statement of Commercial Support

This activity is supported by an educational grant from GlaxoSmithKline LLC.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education and GlaxoSmithKline do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education or GlaxoSmithKline. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions about the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or information@integrityce.com.

For information about the ANCC or ACPE accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

0.25 CME
Medical Education Resources (MER)
Bridging the Gap Between Diabetic Primary Care and Retinal Specialty Practice - Vision-Saving Treatments for Patients With Diabetes

Bridging the Gap Between Diabetic Primary Care and Retinal Specialty Practice - Vision-Saving Treatments for Patients With Diabetes

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: June 19, 2020
Expires: June 19, 2021
15 minutes to complete

Accredited By

Jointly Provided By

Creative Services Provided By

Target Audience

Primary Care Physicians

Learning Objectives

Describe the unmet need for diabetic eye care and the risks associated with delayed intervention.

Activity Description

Infinity Medical Education™, Medical Education Resources, and infograph-ed™ have created a highly engaging, interactive learning experience. A series of three modular infographics will build on each other. The goal of this activity is to educate primary care clinicians on the most critical needs in diabetic care that are not being regularly met. Namely, patients are missing annual diabetic eye exams and are losing vision as a result. Primary care physicians are at the front line of diabetic care, directing patients through their healthcare journey, and these clinicians provide an essential touchpoint at which patients with diabetes can and should be directed to eye care providers.

Statement of Educational Need

Diabetes is a growing health crisis and primary care physicians are at the front line, directing patients through several other steps along their healthcare journey. Unfortunately, one of the most critical needs in diabetic care is not regularly met. Specifically, patients are missing annual diabetic eye exams and are losing vision as a result. Countless patients go blind because they either never enter the treatment continuum or they miss follow-up appointments. This comes at a time when retinal specialists are calling for treatment at earlier stages of disease.

The primary care visit is an essential touchpoint at which patients with diabetes can and should be directed to eye care providers who can deliver much-needed diagnostic services and treatments. This interactive learning opportunity will engage physicians and inspire a more proactive approach to patient education. Physicians will learn the unmet need for diabetic eye care and the risks associated with delayed intervention. Additionally, they will become well-acquainted with the science behind vision-saving treatments for patients with diabetic macular edema and diabetic retinopathy. Furthermore, this program will emphasize the potential advantages of moving patients into treatment sooner rather than later.

Topics

  • Treatments for DME
  • Treatments for DR
  • Types of anti-vascular endothelial growth factor (VEGF) drugs
  • Important considerations in anti-VEGF therapy

Faculty

W. Lloyd Clark, MD
Retina Specialist with Palmetto Retina Center
West Columbia, SC


Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) and Infinity Medical Education require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to MER policy. MER is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

W. Lloyd Clark, MD, has disclosed grant research funded by Genentech, Regeneron, and Roche. Additionally, he has received consulting fees from and speaks on speaker bureaus for Genentech, Regeneron and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her/his presentation.

Medical Education Resources’ planners and managers have disclosed no relevant financial relationships.

The employees of Infinity Medical Education, LLC have disclosed no relevant financial relationships.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and Infinity Medical Education. MER is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Instructions for Receiving Credit

A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 66% or better.

Statement of Commercial Support

This continuing medical education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

Medical Education Resources
http://cmepartner.org/contact or call toll-free: 800-421-3756

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: June 19, 2020
Expires: June 19, 2021
15 minutes to complete

Accredited By

Jointly Provided By

Creative Services Provided By

Target Audience

Primary Care Physicians

Learning Objectives

Describe the unmet need for diabetic eye care and the risks associated with delayed intervention.

Activity Description

Infinity Medical Education™, Medical Education Resources, and infograph-ed™ have created a highly engaging, interactive learning experience. A series of three modular infographics will build on each other. The goal of this activity is to educate primary care clinicians on the most critical needs in diabetic care that are not being regularly met. Namely, patients are missing annual diabetic eye exams and are losing vision as a result. Primary care physicians are at the front line of diabetic care, directing patients through their healthcare journey, and these clinicians provide an essential touchpoint at which patients with diabetes can and should be directed to eye care providers.

Statement of Educational Need

Diabetes is a growing health crisis and primary care physicians are at the front line, directing patients through several other steps along their healthcare journey. Unfortunately, one of the most critical needs in diabetic care is not regularly met. Specifically, patients are missing annual diabetic eye exams and are losing vision as a result. Countless patients go blind because they either never enter the treatment continuum or they miss follow-up appointments. This comes at a time when retinal specialists are calling for treatment at earlier stages of disease.

The primary care visit is an essential touchpoint at which patients with diabetes can and should be directed to eye care providers who can deliver much-needed diagnostic services and treatments. This interactive learning opportunity will engage physicians and inspire a more proactive approach to patient education. Physicians will learn the unmet need for diabetic eye care and the risks associated with delayed intervention. Additionally, they will become well-acquainted with the science behind vision-saving treatments for patients with diabetic macular edema and diabetic retinopathy. Furthermore, this program will emphasize the potential advantages of moving patients into treatment sooner rather than later.

Topics

  • Treatments for DME
  • Treatments for DR
  • Types of anti-vascular endothelial growth factor (VEGF) drugs
  • Important considerations in anti-VEGF therapy

Faculty

W. Lloyd Clark, MD
Retina Specialist with Palmetto Retina Center
West Columbia, SC


Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) and Infinity Medical Education require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to MER policy. MER is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

W. Lloyd Clark, MD, has disclosed grant research funded by Genentech, Regeneron, and Roche. Additionally, he has received consulting fees from and speaks on speaker bureaus for Genentech, Regeneron and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her/his presentation.

Medical Education Resources’ planners and managers have disclosed no relevant financial relationships.

The employees of Infinity Medical Education, LLC have disclosed no relevant financial relationships.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and Infinity Medical Education. MER is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Instructions for Receiving Credit

A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 66% or better.

Statement of Commercial Support

This continuing medical education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

Medical Education Resources
http://cmepartner.org/contact or call toll-free: 800-421-3756

0.25 CME
Medical Education Resources (MER)
Bridging the Gap Between Diabetic Primary Care and Retinal Specialty Practice - Unmet Eye Care Needs in Diabetes Mellitus

Bridging the Gap Between Diabetic Primary Care and Retinal Specialty Practice - Unmet Eye Care Needs in Diabetes Mellitus

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: May 15, 2020
Expires: May 15, 2021
15 minutes to complete

Accredited By

Jointly Provided By

Creative Services Provided By

Target Audience

Primary Care Physicians

Learning Objectives

Describe the unmet need for diabetic eye care and the risks associated with delayed intervention.

Activity Description

Infinity Medical Education™ and infograph-ed™ have created a highly engaging, interactive learning experience. A series of three modular infographics will build on each other. The goal of this activity is to educate primary care clinicians on the most critical needs in diabetic care that are not being regularly met. Namely, patients are missing annual diabetic eye exams and are losing vision as a result. Primary care physicians are at the front line of diabetic care, directing patients through their healthcare journey, and these clinicians provide an essential touchpoint at which patients with diabetes can and should be directed to eye care providers.

Statement of Educational Need

Diabetes is a growing health crisis and primary care physicians are at the front line, directing patients through several other steps along their healthcare journey. Unfortunately, one of the most critical needs in diabetic care is not regularly met. Specifically, patients are missing annual diabetic eye exams and are losing vision as a result. Countless patients go blind because they either never enter the treatment continuum or they miss follow-up appointments. This comes at a time when retinal specialists are calling for treatment at earlier stages of disease.

The primary care visit is an essential touchpoint at which patients with diabetes can and should be directed to eye care providers who can deliver much-needed diagnostic services and treatments. This interactive learning opportunity will engage physicians and inspire a more proactive approach to patient education. Physicians will learn the unmet need for diabetic eye care and the risks associated with delayed intervention. Additionally, they will become well-acquainted with the science behind vision-saving treatments for patients with diabetic macular edema and diabetic retinopathy. Furthermore, this program will emphasize the potential advantages of moving patients into treatment sooner rather than later.

Topics

  • Growing incidence of diabetes
  • Diabetic retinopathy—a leading cause of blindness
  • Lack of awareness of eye disease risk among patients with diabetes
  • Dilated eye exam recommendations and frequency
  • Management and follow-up obstacles

Faculty

Carl D. Regillo, MD, FACS
Director, Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Philadelphia, Pennsylvania


Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) and Infinity Medical Education require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to MER policy. MER is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Carl D. Regillo, MD, FACS, has disclosed grant research funded by Allergan, Genentech, Novartis, Regeneron, Kodiak, Chengdu Kanghong, Opthea, Adverum, RegenxBio, and Graybug. Additionally, he has received consulting fees from Allergan, Genentech, Novartis, Chendu Kanghong, Kodiak, Adverum, and Graybug. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her/his presentation.

Medical Education Resources’ planners and managers have disclosed no relevant financial relationships.

The employees of Infinity Medical Education, LLC have disclosed no relevant financial relationships.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and Infinity Medical Education. MER is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Instructions for Receiving Credit

A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Statement of Commercial Support

This continuing medical education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

Medical Education Resources
http://cmepartner.org/contact or call toll-free: 800-421-3756

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: May 15, 2020
Expires: May 15, 2021
15 minutes to complete

Accredited By

Jointly Provided By

Creative Services Provided By

Target Audience

Primary Care Physicians

Learning Objectives

Describe the unmet need for diabetic eye care and the risks associated with delayed intervention.

Activity Description

Infinity Medical Education™ and infograph-ed™ have created a highly engaging, interactive learning experience. A series of three modular infographics will build on each other. The goal of this activity is to educate primary care clinicians on the most critical needs in diabetic care that are not being regularly met. Namely, patients are missing annual diabetic eye exams and are losing vision as a result. Primary care physicians are at the front line of diabetic care, directing patients through their healthcare journey, and these clinicians provide an essential touchpoint at which patients with diabetes can and should be directed to eye care providers.

Statement of Educational Need

Diabetes is a growing health crisis and primary care physicians are at the front line, directing patients through several other steps along their healthcare journey. Unfortunately, one of the most critical needs in diabetic care is not regularly met. Specifically, patients are missing annual diabetic eye exams and are losing vision as a result. Countless patients go blind because they either never enter the treatment continuum or they miss follow-up appointments. This comes at a time when retinal specialists are calling for treatment at earlier stages of disease.

The primary care visit is an essential touchpoint at which patients with diabetes can and should be directed to eye care providers who can deliver much-needed diagnostic services and treatments. This interactive learning opportunity will engage physicians and inspire a more proactive approach to patient education. Physicians will learn the unmet need for diabetic eye care and the risks associated with delayed intervention. Additionally, they will become well-acquainted with the science behind vision-saving treatments for patients with diabetic macular edema and diabetic retinopathy. Furthermore, this program will emphasize the potential advantages of moving patients into treatment sooner rather than later.

Topics

  • Growing incidence of diabetes
  • Diabetic retinopathy—a leading cause of blindness
  • Lack of awareness of eye disease risk among patients with diabetes
  • Dilated eye exam recommendations and frequency
  • Management and follow-up obstacles

Faculty

Carl D. Regillo, MD, FACS
Director, Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Philadelphia, Pennsylvania


Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) and Infinity Medical Education require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to MER policy. MER is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Carl D. Regillo, MD, FACS, has disclosed grant research funded by Allergan, Genentech, Novartis, Regeneron, Kodiak, Chengdu Kanghong, Opthea, Adverum, RegenxBio, and Graybug. Additionally, he has received consulting fees from Allergan, Genentech, Novartis, Chendu Kanghong, Kodiak, Adverum, and Graybug. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her/his presentation.

Medical Education Resources’ planners and managers have disclosed no relevant financial relationships.

The employees of Infinity Medical Education, LLC have disclosed no relevant financial relationships.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and Infinity Medical Education. MER is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Instructions for Receiving Credit

A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Statement of Commercial Support

This continuing medical education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

Medical Education Resources
http://cmepartner.org/contact or call toll-free: 800-421-3756

0.25 CME / CE
American Heart Association
HeartBEATS from Lifelong Learning™ Heart Failure Guidelines Series: Episode 3

HeartBEATS from Lifelong Learning™ Heart Failure Guidelines Series: Episode 3

Start

Activity Details

Free CME/CE
0.25 AMA PRA Category 1 Credits
0.25 Contact Hour(s)
Released: September 1, 2018
Expires: September 1, 2021
20 minutes to complete

Accredited By


American Heart Association

Target Audience

Physicians and nurses specific to treating patients with heart failure.

Learning Objectives

At the completion of this course, the learner will be able to:

  • List treatments of hypertension in HFrEF.
  • Describe treatment of HFpEF from hypertension and atrial fibrillation.
  • Discuss the 2017 guideline recommendations for treatment of anemia and sleep-disordered breathing.
  • Explain the role of novel pharmacological therapies in HFrEF.
  • Identify treatment of Advanced Heart Failure.

Activity Description

This series focuses on recent studies and the latest evidence for current best practices in reducing preventable hospital readmissions in heart failure. Experts address challenges, areas identified as greatest need from the Providing Healthcare Teams with Learning and Education to Impact Patient Care webinar and reinforce practice and behavior aspects that will contribute to improved patient care and outcomes.

Statement of Educational Need

With the release of new guidelines, healthcare professionals will need education and learning in order to change practice and behavior for the care and treatment of patients with or at risk of cardiovascular disease. This educational series is an important opportunity to educate healthcare professionals on evidence-based guidelines, especially those that are newly released, addressing changes, evidence, and action that can be put into practice immediately to impact patient care and outcomes.

Agenda

Dr. Butler, 9:47 minutes: Expert discussion
Dr. Chow, 10:03 minutes: Expert discussion

Presenters

Javed Butler, MD, MPH, MBA, FACC, FAHA, FESC
Co-Director of the Heart Institute
Chief of Division of Cardiology
Stony Brook University
Stony Brook, NY


Sheryl Chow, PharmD, FCCP, FAHA, FHFSA, BCPS AQ-Cardiology
Associate Professor
Pharmacy Practice and Administration
Western University of Health Sciences
Pomona, CA

Planning Committee (Content Developers)

Mark Drazner, MD – Planning Committee Chair, course author
Clinical Chief of Cardiology
Medical Director of the LVAD and Cardiac Transplantation Program
Professor of Internal Medicine
UT Southwestern

Deborah Crabbe, MD - Planning Committee, course author
Professor of Medicine
Lewis Katz School of Medicine
Temple University

Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA - Planning Committee, course author
Adjunct Assistant Clinical Professor
University of Illinois at Chicago School of Medicine

Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA - Planning Committee, course author
Associate Chief Nursing Officer
Research and Innovation
Cleveland Clinic Health System, Kaufman Center for Heart Failure

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represent the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Mark Drazner, MD – No disclosures
Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA – Employed by Roche Diagnostics Corp.
Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA – Novartis: Speaker bureau, consultant on research projects; Amgen: Speaker bureau
Deborah Crabbe, MD – No disclosures
Javed Butler, MD, MPH, MBA, FACC, FAHA, FESC – Amgen, Astra Zeneca, Bayer, Boelinger, Bristol Meyer Squib, Merck, Novartis: Consultant/Advisory board
Sheryl Chow, PharmD, FCCP, FAHA, FHFSA, BCPS AQ-Cardiology – Novartis: Consultant

Accreditation Statements

ORIGINAL RELEASE DATE: 09/01/2018

TERMINATION DATE: 09/01/2021

LAST REVIEW DATE: August 2018

JOINT ACCREDITATION TERM: 09/01/2018 – 09/01/2021

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 0.25 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

Participation and Successful Completion

Successful completion of this CME/CE activity includes the following:

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 75%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Novartis Pharmaceuticals Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Fred Porta
Program Manager, Lifelong Learning
AHA National Center
fred.porta@heart.org
817-412-1941

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Activity Details

Free CME/CE
0.25 AMA PRA Category 1 Credits
0.25 Contact Hour(s)
Released: September 1, 2018
Expires: September 1, 2021
20 minutes to complete

Accredited By


American Heart Association

Target Audience

Physicians and nurses specific to treating patients with heart failure.

Learning Objectives

At the completion of this course, the learner will be able to:

  • List treatments of hypertension in HFrEF.
  • Describe treatment of HFpEF from hypertension and atrial fibrillation.
  • Discuss the 2017 guideline recommendations for treatment of anemia and sleep-disordered breathing.
  • Explain the role of novel pharmacological therapies in HFrEF.
  • Identify treatment of Advanced Heart Failure.

Activity Description

This series focuses on recent studies and the latest evidence for current best practices in reducing preventable hospital readmissions in heart failure. Experts address challenges, areas identified as greatest need from the Providing Healthcare Teams with Learning and Education to Impact Patient Care webinar and reinforce practice and behavior aspects that will contribute to improved patient care and outcomes.

Statement of Educational Need

With the release of new guidelines, healthcare professionals will need education and learning in order to change practice and behavior for the care and treatment of patients with or at risk of cardiovascular disease. This educational series is an important opportunity to educate healthcare professionals on evidence-based guidelines, especially those that are newly released, addressing changes, evidence, and action that can be put into practice immediately to impact patient care and outcomes.

Agenda

Dr. Butler, 9:47 minutes: Expert discussion
Dr. Chow, 10:03 minutes: Expert discussion

Presenters

Javed Butler, MD, MPH, MBA, FACC, FAHA, FESC
Co-Director of the Heart Institute
Chief of Division of Cardiology
Stony Brook University
Stony Brook, NY


Sheryl Chow, PharmD, FCCP, FAHA, FHFSA, BCPS AQ-Cardiology
Associate Professor
Pharmacy Practice and Administration
Western University of Health Sciences
Pomona, CA

Planning Committee (Content Developers)

Mark Drazner, MD – Planning Committee Chair, course author
Clinical Chief of Cardiology
Medical Director of the LVAD and Cardiac Transplantation Program
Professor of Internal Medicine
UT Southwestern

Deborah Crabbe, MD - Planning Committee, course author
Professor of Medicine
Lewis Katz School of Medicine
Temple University

Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA - Planning Committee, course author
Adjunct Assistant Clinical Professor
University of Illinois at Chicago School of Medicine

Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA - Planning Committee, course author
Associate Chief Nursing Officer
Research and Innovation
Cleveland Clinic Health System, Kaufman Center for Heart Failure

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represent the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Mark Drazner, MD – No disclosures
Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA – Employed by Roche Diagnostics Corp.
Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA – Novartis: Speaker bureau, consultant on research projects; Amgen: Speaker bureau
Deborah Crabbe, MD – No disclosures
Javed Butler, MD, MPH, MBA, FACC, FAHA, FESC – Amgen, Astra Zeneca, Bayer, Boelinger, Bristol Meyer Squib, Merck, Novartis: Consultant/Advisory board
Sheryl Chow, PharmD, FCCP, FAHA, FHFSA, BCPS AQ-Cardiology – Novartis: Consultant

Accreditation Statements

ORIGINAL RELEASE DATE: 09/01/2018

TERMINATION DATE: 09/01/2021

LAST REVIEW DATE: August 2018

JOINT ACCREDITATION TERM: 09/01/2018 – 09/01/2021

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 0.25 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

Participation and Successful Completion

Successful completion of this CME/CE activity includes the following:

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 75%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Novartis Pharmaceuticals Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Fred Porta
Program Manager, Lifelong Learning
AHA National Center
fred.porta@heart.org
817-412-1941

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.25 CME / CE
American Heart Association
HeartBEATS from Lifelong Learning™ Heart Failure Guidelines Series: Episode 1

HeartBEATS from Lifelong Learning™ Heart Failure Guidelines Series: Episode 1

Start

Activity Details

Free CME/CE
0.25 AMA PRA Category 1 Credits
0.25 Contact Hour(s)
Released: September 1, 2018
Expires: September 1, 2021
19 minutes to complete

Accredited By


American Heart Association

Target Audience

Physicians and nurses specific to treating patients with heart failure.

Learning Objectives

At the completion of this course, the learner will be able to:

  • List treatments of hypertension in HFrEF.
  • Describe treatment of HFpEF from hypertension and atrial fibrillation.
  • Discuss the 2017 guideline recommendations for treatment of anemia and sleep-disordered breathing.
  • Explain the role of novel pharmacological therapies in HFrEF.
  • Identify treatment of Advanced Heart Failure.

Activity Description

This series focuses on recent studies and the latest evidence for current best practices in reducing preventable hospital readmissions in heart failure. Experts address challenges, areas identified as greatest need from the Providing Healthcare Teams with Learning and Education to Impact Patient Care webinar and reinforce practice and behavior aspects that will contribute to improved patient care and outcomes.

Statement of Educational Need

With the release of new guidelines, healthcare professionals will need education and learning in order to change practice and behavior for the care and treatment of patients with or at risk of cardiovascular disease. This educational series is an important opportunity to educate healthcare professionals on evidence-based guidelines, especially those that are newly released, addressing changes, evidence, and action that can be put into practice immediately to impact patient care and outcomes.

Agenda

Dr. Migliore, 9:47 minutes: Expert discussion
Dr. Martínez, 9:31 minutes: Expert discussion

Presenters

Ricardo Alberto Migliore, MD
Head of Diagnosis & Treatment, Cardiology Services
Hospital Interzonal de Agudos “Eva Perón”
San Martin, Buenos Aires, Argentina


Felipe Martínez, MD, FACC, FECS
Professor of Medicine
Cordoba National University
Director of Rusculleda Foundation
Cordoba, Argentina

Planning Committee (Content Developers)

Mark Drazner, MD – Planning Committee Chair, course author
Clinical Chief of Cardiology
Medical Director of the LVAD and Cardiac Transplantation Program
Professor of Internal Medicine
UT Southwestern

Deborah Crabbe, MD - Planning Committee, course author
Professor of Medicine
Lewis Katz School of Medicine
Temple University

Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA - Planning Committee, course author
Adjunct Assistant Clinical Professor
University of Illinois at Chicago School of Medicine

Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA - Planning Committee, course author
Associate Chief Nursing Officer
Research and Innovation
Cleveland Clinic Health System, Kaufman Center for Heart Failure

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represent the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Mark Drazner, MD – No disclosures
Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA – Employed by Roche Diagnostics Corp.
Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA – Novartis: Speaker bureau, consultant on research projects; Amgen: Speaker bureau
Deborah Crabbe, MD – No disclosures
Ricardo Alberto Migliore, MD – No disclosures
Felipe Martínez, MD, FACC, FECS – No disclosures

Accreditation Statements

ORIGINAL RELEASE DATE: 09/01/2018

TERMINATION DATE: 09/01/2021

LAST REVIEW DATE: August 2018

JOINT ACCREDITATION TERM: 09/01/2018 – 09/01/2021

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 0.25 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

Participation and Successful Completion

Successful completion of this CME/CE activity includes the following:

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 75%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Novartis Pharmaceuticals Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Fred Porta
Program Manager, Lifelong Learning
AHA National Center
fred.porta@heart.org
817-412-1941

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Activity Details

Free CME/CE
0.25 AMA PRA Category 1 Credits
0.25 Contact Hour(s)
Released: September 1, 2018
Expires: September 1, 2021
19 minutes to complete

Accredited By


American Heart Association

Target Audience

Physicians and nurses specific to treating patients with heart failure.

Learning Objectives

At the completion of this course, the learner will be able to:

  • List treatments of hypertension in HFrEF.
  • Describe treatment of HFpEF from hypertension and atrial fibrillation.
  • Discuss the 2017 guideline recommendations for treatment of anemia and sleep-disordered breathing.
  • Explain the role of novel pharmacological therapies in HFrEF.
  • Identify treatment of Advanced Heart Failure.

Activity Description

This series focuses on recent studies and the latest evidence for current best practices in reducing preventable hospital readmissions in heart failure. Experts address challenges, areas identified as greatest need from the Providing Healthcare Teams with Learning and Education to Impact Patient Care webinar and reinforce practice and behavior aspects that will contribute to improved patient care and outcomes.

Statement of Educational Need

With the release of new guidelines, healthcare professionals will need education and learning in order to change practice and behavior for the care and treatment of patients with or at risk of cardiovascular disease. This educational series is an important opportunity to educate healthcare professionals on evidence-based guidelines, especially those that are newly released, addressing changes, evidence, and action that can be put into practice immediately to impact patient care and outcomes.

Agenda

Dr. Migliore, 9:47 minutes: Expert discussion
Dr. Martínez, 9:31 minutes: Expert discussion

Presenters

Ricardo Alberto Migliore, MD
Head of Diagnosis & Treatment, Cardiology Services
Hospital Interzonal de Agudos “Eva Perón”
San Martin, Buenos Aires, Argentina


Felipe Martínez, MD, FACC, FECS
Professor of Medicine
Cordoba National University
Director of Rusculleda Foundation
Cordoba, Argentina

Planning Committee (Content Developers)

Mark Drazner, MD – Planning Committee Chair, course author
Clinical Chief of Cardiology
Medical Director of the LVAD and Cardiac Transplantation Program
Professor of Internal Medicine
UT Southwestern

Deborah Crabbe, MD - Planning Committee, course author
Professor of Medicine
Lewis Katz School of Medicine
Temple University

Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA - Planning Committee, course author
Adjunct Assistant Clinical Professor
University of Illinois at Chicago School of Medicine

Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA - Planning Committee, course author
Associate Chief Nursing Officer
Research and Innovation
Cleveland Clinic Health System, Kaufman Center for Heart Failure

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represent the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Mark Drazner, MD – No disclosures
Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA – Employed by Roche Diagnostics Corp.
Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA – Novartis: Speaker bureau, consultant on research projects; Amgen: Speaker bureau
Deborah Crabbe, MD – No disclosures
Ricardo Alberto Migliore, MD – No disclosures
Felipe Martínez, MD, FACC, FECS – No disclosures

Accreditation Statements

ORIGINAL RELEASE DATE: 09/01/2018

TERMINATION DATE: 09/01/2021

LAST REVIEW DATE: August 2018

JOINT ACCREDITATION TERM: 09/01/2018 – 09/01/2021

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 0.25 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

Participation and Successful Completion

Successful completion of this CME/CE activity includes the following:

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 75%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Novartis Pharmaceuticals Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Fred Porta
Program Manager, Lifelong Learning
AHA National Center
fred.porta@heart.org
817-412-1941

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.25 CME / CE
American Heart Association
HeartBEATS from Lifelong Learning™ Heart Failure Guidelines Series: Episode 2

HeartBEATS from Lifelong Learning™ Heart Failure Guidelines Series: Episode 2

Start

Activity Details

Free CME/CE
0.25 AMA PRA Category 1 Credits
0.25 Contact Hour(s)
Released: September 1, 2018
Expires: September 1, 2021
16 minutes to complete

Accredited By


American Heart Association

Target Audience

Physicians and nurses specific to treating patients with heart failure.

Learning Objectives

At the completion of this course, the learner will be able to:

  • List treatments of hypertension in HFrEF.
  • Describe treatment of HFpEF from hypertension and atrial fibrillation.
  • Discuss the 2017 guideline recommendations for treatment of anemia and sleep-disordered breathing.
  • Explain the role of novel pharmacological therapies in HFrEF.
  • Identify treatment of Advanced Heart Failure.

Activity Description

This series focuses on recent studies and the latest evidence for current best practices in reducing preventable hospital readmissions in heart failure. Experts address challenges, areas identified as greatest need from the Providing Healthcare Teams with Learning and Education to Impact Patient Care webinar and reinforce practice and behavior aspects that will contribute to improved patient care and outcomes.

Statement of Educational Need

With the release of new guidelines, healthcare professionals will need education and learning in order to change practice and behavior for the care and treatment of patients with or at risk of cardiovascular disease. This educational series is an important opportunity to educate healthcare professionals on evidence-based guidelines, especially those that are newly released, addressing changes, evidence, and action that can be put into practice immediately to impact patient care and outcomes.

Agenda

Dr. Fonarow, 13:23 minutes: Expert discussion
Dr. Ventura, 2:50 minutes: Expert discussion

Presenters

Gregg Fonarow, MD, FACC, FAHA, FHFSA
Co-Chief of Cardiology
Director, Ahmanson-UCLA Preventative Cardiomyopathy Center
Ronald Reagan UCLA Medical Center
Los Angeles, CA


Hector Ventura, MD
Section Head, Cardiomyopathy and Heart Transplantation
Ochsner Medical Center
New Orleans, LA

Planning Committee (Content Developers)

Mark Drazner, MD – Planning Committee Chair, course author
Clinical Chief of Cardiology
Medical Director of the LVAD and Cardiac Transplantation Program
Professor of Internal Medicine
UT Southwestern

Deborah Crabbe, MD - Planning Committee, course author
Professor of Medicine
Lewis Katz School of Medicine
Temple University

Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA - Planning Committee, course author
Adjunct Assistant Clinical Professor
University of Illinois at Chicago School of Medicine

Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA - Planning Committee, course author
Associate Chief Nursing Officer
Research and Innovation
Cleveland Clinic Health System, Kaufman Center for Heart Failure

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represent the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Mark Drazner, MD – No disclosures
Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA – Employed by Roche Diagnostics Corp.
Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA – Novartis: Speaker bureau, consultant on research projects; Amgen: Speaker bureau
Deborah Crabbe, MD – No disclosures
Greg Fonarow, MD, FACC, FAHA, FHFSA – Novartis, Medtronic, Janssen, Bayer, ST. Jude, Amgen: Consultant/Advisory Board
Hector Ventura, MD – No disclosures

Accreditation Statements

ORIGINAL RELEASE DATE: 09/01/2018

TERMINATION DATE: 09/01/2021

LAST REVIEW DATE: August 2018

JOINT ACCREDITATION TERM: 09/01/2018 – 09/01/2021

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 0.25 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

Participation and Successful Completion

Successful completion of this CME/CE activity includes the following:

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 75%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Novartis Pharmaceuticals Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Fred Porta
Program Manager, Lifelong Learning
AHA National Center
fred.porta@heart.org
817-412-1941

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Activity Details

Free CME/CE
0.25 AMA PRA Category 1 Credits
0.25 Contact Hour(s)
Released: September 1, 2018
Expires: September 1, 2021
16 minutes to complete

Accredited By


American Heart Association

Target Audience

Physicians and nurses specific to treating patients with heart failure.

Learning Objectives

At the completion of this course, the learner will be able to:

  • List treatments of hypertension in HFrEF.
  • Describe treatment of HFpEF from hypertension and atrial fibrillation.
  • Discuss the 2017 guideline recommendations for treatment of anemia and sleep-disordered breathing.
  • Explain the role of novel pharmacological therapies in HFrEF.
  • Identify treatment of Advanced Heart Failure.

Activity Description

This series focuses on recent studies and the latest evidence for current best practices in reducing preventable hospital readmissions in heart failure. Experts address challenges, areas identified as greatest need from the Providing Healthcare Teams with Learning and Education to Impact Patient Care webinar and reinforce practice and behavior aspects that will contribute to improved patient care and outcomes.

Statement of Educational Need

With the release of new guidelines, healthcare professionals will need education and learning in order to change practice and behavior for the care and treatment of patients with or at risk of cardiovascular disease. This educational series is an important opportunity to educate healthcare professionals on evidence-based guidelines, especially those that are newly released, addressing changes, evidence, and action that can be put into practice immediately to impact patient care and outcomes.

Agenda

Dr. Fonarow, 13:23 minutes: Expert discussion
Dr. Ventura, 2:50 minutes: Expert discussion

Presenters

Gregg Fonarow, MD, FACC, FAHA, FHFSA
Co-Chief of Cardiology
Director, Ahmanson-UCLA Preventative Cardiomyopathy Center
Ronald Reagan UCLA Medical Center
Los Angeles, CA


Hector Ventura, MD
Section Head, Cardiomyopathy and Heart Transplantation
Ochsner Medical Center
New Orleans, LA

Planning Committee (Content Developers)

Mark Drazner, MD – Planning Committee Chair, course author
Clinical Chief of Cardiology
Medical Director of the LVAD and Cardiac Transplantation Program
Professor of Internal Medicine
UT Southwestern

Deborah Crabbe, MD - Planning Committee, course author
Professor of Medicine
Lewis Katz School of Medicine
Temple University

Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA - Planning Committee, course author
Adjunct Assistant Clinical Professor
University of Illinois at Chicago School of Medicine

Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA - Planning Committee, course author
Associate Chief Nursing Officer
Research and Innovation
Cleveland Clinic Health System, Kaufman Center for Heart Failure

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represent the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Mark Drazner, MD – No disclosures
Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA – Employed by Roche Diagnostics Corp.
Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA – Novartis: Speaker bureau, consultant on research projects; Amgen: Speaker bureau
Deborah Crabbe, MD – No disclosures
Greg Fonarow, MD, FACC, FAHA, FHFSA – Novartis, Medtronic, Janssen, Bayer, ST. Jude, Amgen: Consultant/Advisory Board
Hector Ventura, MD – No disclosures

Accreditation Statements

ORIGINAL RELEASE DATE: 09/01/2018

TERMINATION DATE: 09/01/2021

LAST REVIEW DATE: August 2018

JOINT ACCREDITATION TERM: 09/01/2018 – 09/01/2021

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 0.25 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

Participation and Successful Completion

Successful completion of this CME/CE activity includes the following:

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 75%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Novartis Pharmaceuticals Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Fred Porta
Program Manager, Lifelong Learning
AHA National Center
fred.porta@heart.org
817-412-1941

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Pages